ArticleInternational journal of nanomedicine2016
Effects of silver nanoparticles in combination with antibiotics on the resistant bacteria Acinetobacter baumannii.
Article in International journal of nanomedicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 145 citations in OpenAlex.
- The impact and safety of encapsulated nanomaterials as a new alternative against carbapenem resistant bacteria. a systematic review.World journal of microbiology & biotechnology · 2024Pooled it
- A Novel Ag/AgCl/AgMicroorganisms · 2026Article
- SMILE-Derived Corneal Stromal Lenticule: Experimental Study as a Corneal Repair Material and Drug Carrier.Cornea · 2026Article
- Bacterial-engineered self-stabilizing ultra-small AgCu nanoparticles for dual antimicrobial-anticancer therapy.Bioactive materials · 2026Article
- Nanosystems for delivery of indolicidin peptide.Frontiers in medical technology · 2026Review
- Polymicrobial Biofilms: Interkingdom Interactions, Resistance and Therapeutic Strategies.Microbial biotechnology · 2025Review
- In-vitro anti-inflammatory and antagonistic efficacy of polymyxin B capped silver nanoparticles in multi drug resistant Acinetobacter baumannii.Scientific reports · 2025Article
- Silver Nanoparticles (AgNPs) fromBiomolecules · 2025Article
- Outsmarting Nightmare: Drug Resistance inThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Review
- Tackling carbapenem-resistantBiotechnology notes (Amsterdam, Netherlands) · 2025Article
- Article
- Silver Nanoparticles in Therapeutics and Beyond: A Review of Mechanism Insights and Applications.Nanomaterials (Basel, Switzerland) · 2024Review
- Recent Advances in the Development of Metal/Metal Oxide Nanoparticle and Antibiotic Conjugates (MNP-Antibiotics) to Address Antibiotic Resistance: Review and Perspective.International journal of molecular sciences · 2024Review
- Genomic Insights into and In Vitro Evaluation of Antimicrobial Combination Therapies for Carbapenem-ResistantMedicina (Kaunas, Lithuania) · 2024Article
- Molecular Analysis of Carbapenem and Aminoglycoside Resistance Genes in Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Green Synthesis of Narrow-Size Silver Nanoparticles UsingInternational journal of molecular sciences · 2024Article
- Nanosilver: An Old Antibacterial Agent with Great Promise in the Fight against Antibiotic Resistance.Antibiotics (Basel, Switzerland) · 2023Review
- Analysis of Capped Silver Nanoparticles Combined with Imipenem against Different Susceptibility Profiles ofAntibiotics (Basel, Switzerland) · 2023Article
- Development of Nanoparticle Adaptation Phenomena in Acinetobacter baumannii: Physiological Change and Defense Response.Microbiology spectrum · 2023Article
- Hybrid Nanosystems of Antibiotics with Metal Nanoparticles-Novel Antibacterial Agents.Molecules (Basel, Switzerland) · 2023Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter baumannii resistance to carbapenem antibiotics is a serious clinical challenge. As a newly developed technology, silver nanoparticles (AgNPs) show some excellent characteristics compared to older treatments, and are a candidate for combating A. baumannii infection. However, its mechanism of action remains unclear. In this study, we combined AgNPs with antibiotics to treat carbapenem-resistant A. baumannii (aba1604). Our results showed that single AgNPs completely inhibited A. baumannii growth at 2.5 μg/mL. AgNP treatment also showed synergistic effects with the antibiotics polymixin B and rifampicin, and an additive effect with tigecyline. In vivo, we found that AgNPs-antibiotic combinations led to better survival ratios in A. baumannii-infected mouse peritonitis models than that by single drug treatment. Finally, we employed different antisense RNA-targeted Escherichia coli strains to elucidate the synergistic mechanism involved in bacterial responses to AgNPs and antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.